3 Stocks Pushing The Drugs Industry Higher

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 96 points (-0.6%) at 16,467 as of Friday, Aug. 1, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 828 issues advancing vs. 2,201 declining with 119 unchanged.

The Drugs industry currently sits down 1.7% versus the S&P 500, which is down 0.6%. On the negative front, top decliners within the industry include Novo Nordisk A/S ( NVO), down 2.6%, Biogen Idec ( BIIB), down 2.2%, Amgen ( AMGN), down 1.8%, Alexion Pharmaceuticals ( ALXN), down 1.6% and GlaxoSmithKline ( GSK), down 1.4%.

TheStreet would like to highlight 3 stocks pushing the industry higher today:

3. Sanofi ( SNY) is one of the companies pushing the Drugs industry higher today. As of noon trading, Sanofi is up $0.60 (1.1%) to $52.87 on heavy volume. Thus far, 3.0 million shares of Sanofi exchanged hands as compared to its average daily volume of 924,400 shares. The stock has ranged in price between $52.76-$53.30 after having opened the day at $53.18 as compared to the previous trading day's close of $52.27.

Sanofi researches, develops, manufactures, and markets healthcare products. The company operates in three segments: Pharmaceuticals, Human Vaccines, and Animal Health. Sanofi has a market cap of $138.2 billion and is part of the health care sector. Shares are down 2.5% year-to-date as of the close of trading on Thursday. Currently there are 2 analysts who rate Sanofi a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Sanofi as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, increase in net income, expanding profit margins and growth in earnings per share. We feel these strengths outweigh the fact that the company has had lackluster performance in the stock itself. Get the full Sanofi Ratings Report now.

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you liked this article you might like

Biotech Mailbag: Buy Dip in T2 Biosystems?

FDA Official Calls for Ending Codeine Use in Kids Cough Products

Big Drug Makers Could Face More Pressure on Codeine Remedies for Kids

Sanofi Has Good Potential Upside

European Pharma Companies Slip on MS Pricing Probe